Solid Tumor Trials: Maintain More Patients with irRECIST Webinar

The Journal for ImmunoTherapy of Cancer recently published ‘Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival,’ marking the first time immune-related criteria show correlation with Overall Survival as its most meaningful endpoint in the treatment of cancer patients.

The publication demonstrates the benefit to a subgroup of patients who otherwise would have foregone treatment and survival benefit when relying solely on RECIST 1.1 instead of irRECIST, as irRECIST takes the entire tumor burden including new tumor growth into consideration.

In this webinar, Dr. Oliver Bohnsack of Calyx – a leading expert on RECIST and irRECIST – discusses the implications of these findings, what it means for oncology clinical development and treatment decision-making, and why irRECIST easily can and shall replace outdated RECIST 1.1 on all solid tumor trials going forward.

WHEN
July 13, 2022
10AM-11AM EDT

Speakers

Oliver Bohnsack, MD PhD MBA image

Oliver Bohnsack, MD PhD MBA

Vice President, Medical Imaging and Head of Oncology, Calyx

In leading the imaging component of oncology studies for Calyx’s global customers, Oliver leverages his experience from supporting over 600 clinical trials – with various indications, complexities, and in all phases of development – which led to the approval of over 20 oncology treatments. He is co-author of the immune-related response criteria (irRC, 2009), first author of irRECIST (2014), and co-author of Comparison of Assessments using RECIST and irRECIST by Eggleton P. et al. (2020).

Stay Updated

Never miss a beat. Sign up to receive emails covering industry news and useful content to help you advance clinical development.

  • This field is for validation purposes and should be left unchanged.